直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

Experience

Securing $240 million and a jury verdict of willful infringement for Promptu in patent case against Comcast

Promptu Systems Corporation

US Synthetic secures ITC exclusion order barring polycrystalline diamond compacts (PDCs)

US Synthetic Corporation

Achieving precedent in preserving valuable patents for Lumify®

Eye Therapies, LLC

Finnegan client Maglula delivers crushing blow to Amazon’s arbitration practices over counterfeit products

Maglula, Ltd.

Finnegan secures $180M for CSRC in complex arbitrations

CSRC et al.

Protecting a blockbuster diabetes treatment for AstraZeneca

AstraZeneca AB

Major victories across IP venues for Volkswagen, Audi, Bentley, and Lamborghini

Audi AG; Audi of America, LLC; Automobili Lamborghini America, LLC; Automobili Lamborghini S.p.A.; Bentley Motors Limited; Bentley Motors, Inc; Volkswagen AG; Volkswagen Group of America, Inc.

Finnegan tees up valuable patents for Eisai, leading to major strategic collaboration agreement

Eisai Co., Ltd.

Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million

Intellia Therapeutics, Inc.

Recent Experience

Experience

Rocket Pharmaceuticals, Inc. v. Beard et al.

Rocket Pharmaceuticals, Inc. v. Beard et al.

3:24-cv-02170, D. Or., Judge Simon

Experience

AbbVie Inc., et al. v. Aurobindo Pharma U.S.A., Inc. et al.

AbbVie Inc., et al. v. Aurobindo Pharma U.S.A., Inc. et al.

3:24-cv-04603, D.N.J., Judges Quraishi, Day
3:24-cv-04662, D.N.J., Judges Quraishi, Day
3:24-cv-04852, D.N.J., Judges Quraishi, Day

Experience

Rocket Pharmaceuticals, Inc. v. Lexeo Therapeutics, Inc., et al.

Rocket Pharmaceuticals, Inc. v. Lexeo Therapeutics, Inc., et al.

1:23-cv-09000, S.D.N.Y., Judges Castel, Aaron

Experience

AbbVie Inc. et al v. Alvotech hf. AbbVie Inc. et al v. Alvotech hf.

1:21-cv-02258, 1:21-cv-02899, N.D. Ill., Judge Lee

Experience

Representative Engagement: Defeating a motion for preliminary injunction in the Western District of Texas -  Cambria Company LLC v. Cosentino SA, 6:20-cv-00894, -00895, -008996, -00897, -01080, W.D. Tex.; IPR2021-00214, -00215, -00216; PGR2021-00010, -90

Defeating a motion for preliminary injunction in the Western District of Texas Defeating a motion for preliminary injunction in the Western District of Texas

6:20-cv-00894, -00895, -00896, -00897, W.D. Tex., Judge Albright
6:20-cv-01080, W.D. Tex., Judge Albright
IPR2021-00214, -00215, -00216; PGR2021-00010, -00090, PTAB, Judges Kalan, Ross, Kaiser

Experience

Bial - Portela & CA S.A. v. Alkem Laboratories Ltd et al. Bial - Portela & CA S.A. v. Alkem Laboratories Ltd et al.

1:18-cv-00304, D. Del., Judges Connolly, Burke

Experience

Grünenthal GmbH v. Teva Pharmaceuticals Grünenthal GmbH v. Teva Pharmaceuticals

1:12-cv-08060, S.D.N.Y., Judges Griesa, Daniels, Gorenstein

Experience

Federal Circuit win for Eli Lilly’s Xigris®, a recombinant form of human Activated Protein Federal Circuit win for Eli Lilly’s Xigris®, a recombinant form of human Activated Protein

08-1248, Fed. Cir., Judges Michel, Newman, Mayer, Lourie, Rader, Bryson, Gajarsa, Linn, Dyk, Prost, Moore
1:02-cv-11280, D. Mass., Judge Zobel

Experience

Pronova Biopharma Norge AS v. Teva Pharmaceuticals USA, Inc. Pronova Biopharma Norge AS v. Teva Pharmaceuticals USA, Inc.

1:09-cv-00286, 1:10-cv-00800, D. Del., Judges Farnan, Robinson, Thynge
12-1498, -1499, Fed. Cir., Judges Dyk, O'Malley, Wallach

Experience

Favorable Federal Circuit ruling confirms the existence of a separate written description requirement Favorable Federal Circuit ruling confirms the existence of a separate written description requirement

1:02-cv-11280, D. Mass., Judge Zobel
08-1248, Fed. Cir., Judges Bryson, Dyk, Gajarsa, Linn, Lourie, Mayer, Michel, Moore, Newman, Prost, Rader

Experience

Eli Lilly and Co. wins challenge to patents covering its osteoporosis drug, Evista® Eli Lilly and Co. wins challenge to patents covering its osteoporosis drug, Evista®

1:06-cv-01017, S.D. Ind., Judges Barker, Magnus-Stinson
09-1071; 10-1005, -1033, Fed. Cir., Judges Linn, Michel, Prost, Rader

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP